Næste

Automatisk afspilning

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1 Visninger • 07/09/23
Del
Indlejre
administrator
administrator
Abonnenter
0

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning